Healthcare | August 03, 2021
Healthium Medtech acquires SGK Lab’s AbGel gelatin business
Complementary business models are the reason for the acquisition
Complementary business models are the reason for the acquisition
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
The company posted net profit of Rs.594.6 crores for the period ended June 30, 2020.
ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
The company reported total income of Rs.1215.73 crores during the period ended June 30, 2021.
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
The patients can check to see if the product purchased by them is genuine or not by scratching the surface and verifying the code through the app or the website
Subscribe To Our Newsletter & Stay Updated
